Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 53 points (0.3%) at 17,715 as of Wednesday, March 11, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,670 issues advancing vs. 1,290 declining with 158 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Mylan ( MYL), up 4.8%, Intercept Pharmaceuticals ( ICPT), up 4.7%, Teva Pharmaceutical Industries ( TEVA), up 3.0%, Actavis ( ACT), up 2.1% and Sanofi ( SNY), up 1.7%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 1.9%, and Novo Nordisk A/S ( NVO), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Salix Pharmaceuticals ( SLXP) is one of the companies pushing the Drugs industry higher today. As of noon trading, Salix Pharmaceuticals is up $0.18 (0.1%) to $157.83 on light volume. Thus far, 766,843 shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $157.55-$157.88 after having opened the day at $157.64 as compared to the previous trading day's close of $157.65.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $10.1 billion and is part of the health care sector. Shares are up 37.2% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts who rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Salix Pharmaceuticals as a hold. Among the primary strengths of the company is its solid stock price performance. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Salix Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Allergan ( AGN) is up $2.58 (1.1%) to $235.53 on average volume. Thus far, 964,574 shares of Allergan exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $233.72-$235.77 after having opened the day at $234.00 as compared to the previous trading day's close of $232.95.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan, Inc. discovers, develops, and commercializes pharmaceuticals, biologics, medical devices, and over-the-counter products in the Unites States and internationally. It operates through two segments, Specialty Pharmaceuticals and Medical Devices. Allergan has a market cap of $70.6 billion and is part of the health care sector. Shares are up 9.6% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate Allergan a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Allergan Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, AbbVie ( ABBV) is up $0.81 (1.4%) to $56.65 on average volume. Thus far, 6.3 million shares of AbbVie exchanged hands as compared to its average daily volume of 10.9 million shares. The stock has ranged in price between $55.66-$56.75 after having opened the day at $56.20 as compared to the previous trading day's close of $55.84.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $88.5 billion and is part of the health care sector. Shares are down 14.7% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts who rate AbbVie a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null